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Abstract 
This study examines the presence of the day-of-the-week effect on daily returns 
of biotechnology stocks over a 16-year period from January 2002 to December 2015. 
Using daily returns from the NASDAQ Biotechnology Index (NBI), we find that the 
stock returns were the lowest on Mondays, and compared to the Mondays the stock 
returns were significantly higher on Wednesdays, Thursdays, and Fridays. The day-
of-the-week effect on returns of biotechnology stocks remained significant even after 
controlling for the Fama-French and Carhart factors. Moreover, the results from using 
the asymmetric GARCH processes reveal that momentum and small-firm effect were 
positively associated with the market risk-adjusted returns of the biotechnology 
stocks during this period. The findings of our study suggest that active portfolio 
managers need to consider the day of the week, momentum, and small-firm effect 
when making trading decisions for biotechnology stocks. Implications for portfolio 
managers, small investors, scholars, and policymakers are included. 
Keywords: Day of the week effect, Behavioral Finance, Market Efficiency, GARCH, 
EGARCH, GJR-GARCH, Biotechnology stocks, NASDAQ NBI, Financial Markets, 
Investments, Returns 
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1. Introduction 
 
          There have been a number of studies over the past four decades that have 
examined the association between variations in stock market returns and the day of 
the trading week in the U.S. and international financial markets (Cross, 1973; French, 
1980; Gibbons & Hess, 1981; Aggarwal & Rivoli, 1989; Solnik & Bousquet, 1990; 
Poshakwale, 1996; Doubois & Louvet, 1996; Berument & Kiymaz, 2001). 
Additionally, the day-of-the-week effect on asset price volatility have been globally 
observed for a number of different asset classes such as treasury bills and bond 
markets, futures markets, crude oil, and real estate (Dyl & Maberly, 1986; Bampinas, 
Fountas, & Panagiotidis, 2015). 
 
Over the past two decades the biotechnology industry has been one of the fastest 
growing sub-sectors in the area of healthcare. These biotechnology companies focus 
on cutting-edge research on finding cures and remedies for complex diseases such as 
cancer, multiple sclerosis, rheumatoid arthritis, and various autoimmune conditions 
(Gitter, 2013). The products launched by these companies subsequent to their 
approval by the Food and Drug Administration (FDA) are amongst the most 
expensive and have accounted for  nearly a fifth of the increase in prescription costs 
over the past decade (Evans, 2010). While publicly traded biotechnology companies 
have benefitted from tremendous innovation and research, these companies’ prices in 
the stock markets have experienced substantial volatility and growth. Although it is 
possible to theoretically hypothesize the association between risk, expected return, 
and innovative activities of the biotechnology companies relative to the market, very 
little empirical literature is currently available that explains the risk and daily price 
movements of the stocks in the biotechnology sector.  The Affordable Care Act 
(ACA), which was signed into law on March 23, 2010, may have long-term policy 
risks for the innovative biotechnology firms; although, a little more than half a decade 
may not be sufficient time to fully understand the effect of ACA on the biotechnology 
companies (Pande, 2014).  
 
This study extends the literature by examining the day-of-the-week effect on 
daily returns of the NASDAQ Biotechnology Index (NBI). Implications of this 
study’s findings for scholars of finance, traders, and individuals investors are 
included. The remainder of the manuscript includes a review of literature, followed 
by a detailed description of the methodology; the results are presented in the next 
section, which is followed by a discussion of the key findings of this study and its 
concluding implications. 
 
2. Literature Review 
 
 In one of the earlies studies on the day-of-the-week effect on stock returns 
Cross (1973) found that between 1953 and 1970, the mean return on the Fridays was 
higher than the mean returns on the Mondays of the weeks during this period. French 
(1980) studied the day-of-the-week effect on stocks during the 1953 and 1977 period 
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and found similar results. Similarly, Gibbons and Hess (1981) found that the mean 
returns on Mondays were lower than the expected returns of the Dow Jones Industrial 
Average stocks. Lakonishok and Levi (1982) proposed that the expected return for 
Mondays should be lower than that of other days as an explanation for this anomaly 
in day-of-the-week differences in stock returns.  In other studies on international 
markets, Solnik and Bousquet (1990) found that the lowest returns in the Paris market 
were on Tuesdays; similarly Jaffe and Westerfield (1985) found that Tuesday had the 
lowest returns in the Australian and Japanese markets as well. 
 
 Berument and Kiymaz (2001) found that volatility in the U.S. markets was 
the highest on Fridays and lowest on Wednesdays. Similarly, Rodriguez (2012) found 
that volatility in South American markets peaked on Fridays and was the lowest on 
Mondays.  Brusa, Liu, & Schulman (2000) found that when compared to Mondays 
when markets experienced a negative return, the stock returns of small firms was 
negative on Fridays while the stock returns of large firms was positive on the Fridays. 
 
Chok and Sun (2007) find that the volatility of the price movements of 
biotechnology firms are susceptible to stock option exercise by company insiders, the 
age of the board members, and the extent of resource dependence of the firms (Chok 
& Sun, 2007). Although healthcare stocks, including the biotechnology stocks, have 
reacted positively to court rulings that have supported the ACA during the 
legislation’s recent legal challenges (Kaufman, 2015), many biotechnology market 
experts expected the biotechnology firm profits to fall following the passage of the 
ACA (Douglas, 2014).  
 
This day-of-the-week effect is inconsistent with the assumptions of efficient 
market hypothesis (Fama, 1965; 1970). One of the key assumptions of the efficient 
market hypothesis is that information is fully accounted for in the price of assets. 
Therefore, it would be impossible to consistently beat the market on a risk-adjusted 
basis. This argument is also central to the Modern Portfolio Theory and the Capital 
Asset Pricing Model (Fabozzi, Gupta, and Markowitz, 2002; Sharpe, 1964; 
Markowitz, 1952; Vernon, Golec, & DiMassi, 2009), which argue that the expected 
return of an asset can be predicted after controlling for U.S. treasury bills, market risk 
premium, the systematic risk (beta) of the stocks, and other factors suggested by 
Fama and French (2004).  
 
It is, therefore, likely that the expected return for the biotechnology stocks 
would be same each day of the week after controlling for the risks, firm size, price 
movements of the market, and the general momentum of stocks. In addition, the 
biotechnology industry was exposed to three unique macroeconomic events that 
coincided with the period from March 30, 2010, through December 31, 2015. Along 
with the rest of the market during this period, the biotechnology industry benefited 
from the phase of market recovery from the great recession of 2008. This period also 
saw low interest rates and the Federal Reserve’s quantitative easing (QE) program. 
But the third macroeconomic event was unique to the healthcare sector, which 
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includes the biotechnology industry, and was as a result of the Affordable Care Act 
legislation of 2010. The ACA was signed into legislation on March 30, 2010. 
Although it is too early to fully understand the economic consequence of ACA on 
biotechnology stock returns, a combination of these three macroeconomic changes 
could possibly alter the performance of biotechnology stocks relative to the market in 
the period after March 30, 2010.   
 
3. Methodology 
 
3.1 Data 
 
The daily information for the S&P 500 index, risk-free rate, Fama-French, and 
momentum factors were obtained from the Center for Research in Security Prices 
(CRSP) database. This study also uses the NBI. The daily price information for the 
NBI was obtained from the Quandl (quandl.com) database. There are 117 companies 
listed in the NBI. Nine of these are large company stocks, another 23 are mid-sized 
company stocks, and the remaining 85 are small company stocks. However, since 
NBI is a value-weighted index, approximately 60% of the NBI’s value is comprised 
of the 10 large company stocks. Approximately 22% of the NBI’s value is composed 
of the 85 small company stocks, and the remaining 18% of its total index value is 
comprised of medium-size company stocks. This study uses data extracted over a 14-
year period starting January 1, 2002 through December 31, 2015. Additional analysis 
is run for the period after March 30, 2010. 
 
 
3.2 Analyses 
 
This paper first presents the descriptive statistics of the sample and the graphs 
for the price movements for the NBI between January 1, 2002 and December 31, 
2015. Binary variables are constructed for the days Monday through Friday. In the 
empirical model, Tuesday through Friday is compared against the reference group of 
the Monday variable. In equation 1, the RNBI variable is examined for the day-of-the-
week effect after risk adjustment by controlling for the additional 3 Fama and French 
factors (2004), and the Carhart (1997) momentum factor.  
 
RNBI=0+ 1(Tuesday)+2(Wednesday)+3(Thursday)+4(Friday)+ ∑ 𝛽5
𝑛
𝐼=𝑖  
RNBI-i +f Rf+ 6(Rm-Rf)+sSMB+hHML+uUMD+e      (1) 
Rf is the risk-free rate. Rm-Rf represents the market risk premium. SMB, or 
‘small minus big’, is the difference in the returns between the small-cap and the large-
cap stocks. HML represents the difference in the returns between value stocks (High 
book-to-market ratio) and growth stocks (low book-to-market ratio). UMD represents 
the difference between the returns of stocks moving up and down in value during the 
period. Additional analyses with the variables are also run for the Pre-ACA (January 
1, 2002 – March 30, 2010), and post-ACA (March 31, 2010 – December 31, 2015) 
periods.  
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However, when an OLS regression is run using equation 1, it assumes a 
constant variance of the error term. Therefore, the OLS model assumes that the error 
term has a ‘0’ mean and is normally distributed. However, studies by Engle (1982) 
and Bollerslev (1987) found that the error term may not be constant in time-series 
models and could possibly vary across time. As a solution, Engle (1982) suggested 
the use of the Autoregressive Conditional Heteroskedastic (ARCH) model. In the 
ARCH model, the conditional variance Qt was dependent on the squared value of the 
past residuals from the equations 1: 
 
Qt=Vc+∑ 𝑉𝑗ℎ𝑗=1 𝑒𝑡−𝑗
2        (2) 
 
Bollerslev (1987) further developed the framework discussed in ARCH by 
constructing variance as a function of the lagged values of Qt and the lagged values 
of et
2 from the return equation. These types of models became known as the 
Generalized ARCH (GARCH) models. Based on equation 2, GARCH model can 
therefore be written as shown below in equation 3: 
 
Qt=Vc+∑ 𝑉𝑚𝑗
ℎ
𝑗=1 Qt-j+∑ 𝑉𝑛𝑗
𝑟
𝑗=1 𝑒𝑡−𝑗
2      (3) 
 
In the equation 3, Vc, Vm, and Vn are positive and hence satisfy the criterion for 
conditional variances (Bollerslev, Chou, & Kroner, 1992). The conditional variances 
measure the volatility of the model. We can then run the GARCH model by adding 
the time varying terms to equations 1 as follows: 
 
RNBI=0+ 1(Tuesday)+2(Wednesday)+3(Thursday)+4(Friday)+f Rf+ 6(Rm-
Rf)+sSMB+hHML+uUMD+∑ 𝑏𝑖𝑅𝑡−1
𝑛
𝐼=1 +Qt-1+et        (4) 
     
Where, 
 
Q
2
t=Vc+V1(Tuesday)+V2(Wednesday)+V3(Thursday)+V4(Friday)+V5 Rf+ V6(Rm-
Rf)+ V7SMB+V8HML+V9UMD+ Va𝑄𝑡−1
2  +Vb𝑒𝑡−1
2                    (5) 
 
In the equation above, the coefficients for Va and Vc should always be positive, but 
Vb can be either a positive or a negative fraction. Another feature of financial asset 
returns is that the increase in volatility in these asset classes is greater in the events of 
losses than it is in the events of gains. This is known as asymmetry (Nelson, 1991; 
Wang & Wang, 2011).  
 
According to Black (1976), a drop in the price of an asset reduced its equity, 
and increased its the debt to equity ratio. This is known as the leverage effect. This 
made the asset riskier and contributed to the increase in its volatility.  Conversely, the 
volatility of an asset reduced in the presence of positive shocks. It is important to note 
that although all models with leverage are asymmetric, not all models with 
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asymmetry have leverage. Bouchaud (2001) found that the leverage effect was 
stronger in the case of indices than it was for individual asset classes.  
 
The GARCH (1, 1) process suggested by Bollerslev (1987) assumes that the 
distributions are Gaussian, and does not account for the presence of asymmetry. To 
account for the presence of asymmetry and leverage, Engle (2001) suggested the use 
of asymmetric GARCH models. However, McAleer (2014) demonstrated that it is not 
possible to show leverage with asymmetric models such as EGARCH and GJR.  
 
The additional analyses in this study include the use these of two asymmetric 
GARCH models mentioned in the previous paragraph. These models are the 
Exponential GARCH (EGARCH) model developed by Nelson (1991), and the GJR 
(Threshold GARCH) model developed by Glosten, Jaganathan, and Runkle (1993). 
Incorporating the conditional variance at time t the EGARCH equation is shown 
below : 
 
Log (Q2t)=Vc+V1(Tuesday)+V2(Wednesday)+V3(Thursday)+V4(Friday)+V5 Rf+ V6(Rm-Rf)+ 
V7SMB+V8HML+V9UMD+ Valog (𝑄𝑡−1
2 ) + Vb|𝑒𝑡−1/𝑄𝑡−1|+(𝑒𝑡−1/𝑄𝑡−1)           (6) 
 
In equation 6, the term |𝑒𝑡−1/𝑄𝑡−1| is the conditional variance, and (𝑒𝑡−1/𝑄𝑡−1) is the 
lagged value of the residual over conditional standard deviation. Log (𝑄𝑡−1
2 ) is the 
logged value of conditional variance.  Asymmetry is present when  > 0. wever 
according to McAleer (2014) and McAleer and Hafner (2014), leverage is not 
possible in the EGARCH model as both variances of the stochastic processes: Vb and  
must be positive. Similarly, the GJR process is shown in equation 7 below:  
 
Q2t=Vc+V1(Tuesday)+V2(Wednesday)+V3(Thursday)+V4(Friday)+V5 Rf+ V6(Rm-Rf)+ 
V7SMB+V8HML+V9UMD+ Va𝑄𝑡−1
2 +Vb𝑒𝑡−1
2  +𝑒𝑡−1
2 𝑑t-1    (7) 
 
In equation 7, dt-1 takes the value of 1 if ut-1 is negative, and 0 otherwise. The effect is 
asymmetric when γ >0. However, as demonstrated by McAleer (2014), it is not possible 
to show leverage using the GJR specification as both variances of the stochastic processes: 
Vb and the  need to be positive.  
   
 
4. Results 
 
4.1 Descriptive Statistics 
 
Table 1 shows the descriptive statistics and t-tests for the day-of-the-week 
returns for the NBI and its comparison to the market index (S&P 500). The results 
show that between 2002 and 2012, the NBI returns on Mondays were significantly 
lower than that of the S&P 500 index. This association was also significant over a 
shorter period from January 1, 2002 to March 30, 2010. However, there was no 
significant difference between the S&P 500 and NBI returns on Mondays after March 
Day of the week effect in US Biotechnology Stocks 
7 
 
30, 2010. Also, not surprisingly, across all days and periods, the small company stock 
dominated NBI returns had a higher standard deviation than the S&P 500 index.  
 
 
Figure 1: NBI daily returns 2002-2015 
  
The returns from figure 1 show the daily NBI returns during 2002–2015. The 
volatility in NBI returns can be observed from this graph in 2002, 2008, and 2015. 
These coincide with periods of volatility for the market in general as shown in figure 
2 below: 
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Figure 2: S&P 500 daily returns 2002-2015 
Figure 3 below shows the closing prices for the market (S&P 500) and the NBI 
indices from 2002 through the end of 2015. The figure shows the price increase and 
the changes in price patterns for the two indices over this period.  
 
 
 
 
Figure 3: Comparison of S&P 500 and NBI Daily closing prices 2002–2015 
 
4.2 Day-of-the-week effect 2002-2015  
 
Results for the day-of-the-week effect are presented in table 2. The first three 
columns of table 2 include the results from the GARCH (1,1) process. Similarly, the 
next three columns include results from the EGARCH (1,1) and the last three 
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columns from table 2 include results from the computed GJR model. The results 
indicate that when compared with Monday, the returns for the NBI were higher on 
Wednesday, Thursday, and Friday across all three types of GARCH processes over 
the entire period of this study. Interestingly, the SMB and Rm-Rf variables were 
positively associated with the biotechnology index returns across all three types of 
GARCH models. Additionally the momentum (UMD) factor was positively 
associated and the HML variable was negatively associated with the biotechnology 
index returns. The lagged returns were significant across all three models.  
 
4.3 Day-of-the-week effect during the Pre-ACA Period  
 
Results for the day-of-the-week effect for the pre_ACA period ending March, 
30th, 2010 are presented in table 3. The first three columns of table 3 include the 
results from the GARCH (1,1) process. Similarly, the next three columns include 
results from the EGARCH (1,1) and the last three columns from table 2 include 
results from the computed GJR model. The results indicate that when compared with 
Monday, the returns for the NBI were higher on Wednesday, Thursday, and Friday 
across all three types of GARCH processes over the entire period of this study. The 
SMB and Rm-Rf variables were aslo positively associated with the biotechnology 
index returns across all three types of GARCH models. Additionally the HML 
variable was negatively associated with the biotechnology index returns. The lagged 
returns were significant across all three models.  
 
4.4 Day-of-the-week effect during the Post-ACA Period  
 
Results for the day-of-the-week effect in the post-ACA era are presented in 
table 4. The first three columns of table 4 include the results from the GARCH (1,1) 
process. Similarly, the next three columns include results from the EGARCH (1,1) 
and the last three columns from table 4 include results from the computed GJR 
model. The results indicate that the SMB and Rm-Rf variables were positively 
associated with the biotechnology index returns across all three types of GARCH 
models. Additionally the HML variable was negatively associated with the 
biotechnology index returns. In the EGARCH model the  was significant and 
negative. 
 
5. Conclusion 
 
The findings from this study indicate the presence of a day-of-the-week effect 
for the biotechnology index during 2002–2015. Another interesting finding is that the 
significance of higher returns for Wednesday, Thursday, and Friday over the returns 
for Mondays persisted for the biotechnology stocks over the 2002–2015 period even 
after controlling for the risk and momentum factors, as suggested by Fama and 
French (2004) and Carhart (1997). During the period after March 30, 2010, after 
ACA was signed and the Federal Reserve’s first round of quantitative easing program 
forced interest rates to historic lows, the day-of-the-week effect disappeared. More 
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research is needed in this area to examine whether this change in the behavior of the 
biotechnology index was due to the related policies that went into effect or to the 
change in economic cycle as the economy recovered from the great recession. In the 
future, studies of market efficiency, perhaps using an event study approach, could 
better extrapolate the effect of the individual policy implications on the price 
movements of the biotechnology stocks. It is also possible that the period after March 
30, 2010 is not long enough to fully estimate the day-of-the week effect. Also, as a 
comparison in the GARCH models for the S&P 500 index returns that was analyzed 
for this period1, no significant day-of-the-week effect were observed after March 30, 
2010. This indicates that the macroeconomic changes associated with this period 
perhaps played a role in the elimination of day-of-the-week effect from the daily 
returns in the market after March 30, 2010. Positive association between SMB and 
UMD factors with the biotechnology index returns during this period correlate with 
momentum of the market and a bias toward the performance of small firms that 
dominate the NASDAQ biotechnology index.  
 
The findings of this study have implications for active portfolio managers and 
market participants. The study indicates that although portfolio managers may 
consider the unique price movements of biotechnology stocks, which usually fall 
lower than the market on Mondays, and relative to Monday, generate higher returns 
on Wednesdays, Thursdays, and Fridays in the long run, there does not appear to be 
any significant day-of-the-week effect present in biotechnology stocks after March 
30, 2010. 
 
The positive association of the small firm effect (SMB) and momentum (UMD) 
factors with the daily biotechnology stock returns indicate that short-term traders may 
have been able to take advantage of market momentum and small firm price 
movements both in the long term and the current period. Given the volatility and high 
reliance on pipeline product development and patent expiration on price valuation of 
biotechnology stocks, it is recommended that small investors either seek professional 
investment advice or pursue a buy-and-hold strategy of a diversified biotechnology 
index fund within their portfolio to benefit from long-term growth expectations.  
 
The findings of this study also have implications for market efficiency which 
would assume the expected return for the biotechnology stocks would be same each 
day of the week after controlling for the risks, firm size, price movements of the 
market, and the general momentum of stocks.  However, the day -of-the-week effect 
persisted for the biotechnology stocks during 2002–2015 even after controlling for 
the risk- and momentum-related factors, suggesting unstable market dynamics and 
opportunities for active managers (Lo, 2004). 
                                                             
1 For brevity the GARCH models testing the day-of-the-week effect on S&P 500 index daily 
returns for the period after March 30, 2010 are not reported separately. 
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The higher cost of the newly approved drugs launched by the biotechnology 
companies has become an important consumer issue and has recently been a subject 
of discussion in the US Presidential debates with some candidates threatening 
legislation to curb the costs of some of the drugs. Consequently, there is a growing 
risk of legislation that may result in lower profit margins for biotech firms. In the 
light of this and other recent policy changes, this study needs to be replicated again in 
a few years and over more stable economic periods to examine the similarities and 
dissimilarities in the performance of biotechnology stocks observed in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day of the week effect in US Biotechnology Stocks 
12 
 
References 
 
Aggarwal, R., & Rivoli, P. (1989). Seasonal and Day‐of‐the‐Week Effects in Four 
Emerging Stock Markets. Financial review, 24(4), 541-550. 
 
Bampinas, G., Fountas, S., & Panagiotidis, T. (2015). The day-of-the-week effect is 
weak: Evidence from the European real estate sector. Journal of Economics and 
Finance, 1-19. 
 
Berument, H., & Kiymaz, H. (2001). The day of the week effect on stock market 
volatility. Journal of economics and finance, 25(2), 181-193. 
 
Black, F. (1976). The pricing of commodity contracts. Journal of financial 
economics, 3(1), 167-179. 
 
Bollerslev, T. (1987). A Conditionally Heteroskedastic Time Series Model for 
Speculative Prices and Rates of Return. The Review of Economics and Statistics, 
69(3), 542-547. 
 
Bollerslev, T., Chou, R. Y., & Kroner, K. F. (1992). ARCH modeling in finance: A 
review of the theory and empirical evidence. Journal of econometrics, 52(1-2), 
5-59. 
 
Bouchaud, J. P., Matacz, A., & Potters, M. (2001). Leverage effect in financial 
markets: The retarded volatility model. Physical review letters, 87(22), 228701. 
 
Brusa, J., Liu, P., & Schulman, C. (2000). The weekend effect,‘reverse’weekend 
effect, and firm size. Journal of Business Finance & Accounting, 27(5‐6), 555-
574. 
 
Carhart, M. M. (1997). On persistence in mutual fund performance. The Journal of 
finance, 52(1), 57-82. 
 
Chok, J. I., & Sun, Q. (2007). Determinants of idiosyncratic volatility for biotech IPO 
firms. Financial Management, 36(4), 107-122. 
 
Cohen, R. B., Polk, C., & Vuolteenaho, T. (2003). The value spread. The Journal of 
Finance, 58(2), 609-642. 
 
Cross, F. (1973). The behavior of stock prices on Fridays and Mondays. Financial 
analysts journal, 29(6), 67-69. 
 
Dubois, M., & Louvet, P. (1996). The day-of-the-week effect: The international 
evidence. Journal of Banking & Finance, 20(9), 1463-1484. 
 
Day of the week effect in US Biotechnology Stocks 
13 
 
Douglas, M. (March, 2014). Will Obamacare harm these biotech stocks? 
Motleyfool.com. Available at: 
http://www.fool.com/investing/general/2014/03/15/will-obamacare-harm-these-
biotech-stocks.aspx 
 
Dyl, E. A., & Maberly, E. D. (1986). The weekly pattern in stock index futures: A 
further note. The Journal of Finance, 41(5), 1149-1152. 
 
Engle, R. F. (1982). Autoregressive Conditional Heteroscedasticity with Estimates of 
the Variance of United Kingdom Inflation. Econometrica, 50(4), 987-1008. 
 
Engle, R. (2001). GARCH 101: The use of ARCH/GARCH models in applied 
econometrics. The Journal of Economic Perspectives, 15(4), 157-168. 
 
Evans, I. (2010). Follow-on biologics: a new play for big pharma: healthcare 2010. 
The Yale journal of biology and medicine, 83(2), 97. 
 
Fabozzi, F. J., Gupta, F., & Markowitz, H. M. (2002). The legacy of modern portfolio 
theory. The Journal of Investing, 11(3), 7-22. 
 
Fama, Eugene F. 1965. “The behavior of stock-market prices”. The Journal of 
Business, 38(1), 34-105. 
Fama, Eugene F. 1970. “Efficient capital markets: A review of theory and empirical 
work.” The Journal of Finance, 25(2), Papers and Proceedings of the Twenty-
Eighth Annual Meeting of the American Financial Association New York, N.Y. 
December 28-30, 1969, 383-417. 
Fama, E. F., & French, K. R. (2004). The capital asset pricing model: Theory and 
evidence. Journal of Economic Perspectives, 18(3), 25-46. 
 
Fama, E. F., & French, K. R. (2006). The value premium and the CAPM. The Journal 
of Finance, 61(5), 2163-2185. 
 
French, K. R. (1980). Stock returns and the weekend effect. Journal of financial 
economics, 8(1), 55-69. 
 
Gibbons, M. R., & Hess, P. (1981). Day of the week effects and asset returns. Journal 
of business, 54(4), 579-596. 
 
Gitter, D. M. (2013). Biopharmaceuticals under the Patient Protection and Affordable 
Care Act: Determining the Appropriate Market and Data Exclusivity Periods. 
Texas Intell. Prop. LJ, 21, 213. 
 
Day of the week effect in US Biotechnology Stocks 
14 
 
Glosten, L. R., Jaganathan, R., & Runkle, D. E. (1993). On the Relation between the 
Expected Value and the Volatility of the Nominal Excess Return on Stocks. 
Journal of Finance, 48(5), 1779-1801. 
 
Jaffe, J., & Westerfield, R. (1985). The Week‐End Effect in Common Stock Returns: 
The International Evidence. Journal of Finance, 40(2), 433-454. 
 
Kaufman, A.C. (June, 2015). Healthcare stocks soar after Obamacare victory in 
Supreme Court. Huffington Post (6/25/2015). Available at: 
http://www.huffingtonpost.com/2015/06/25/obamacare-stocks_n_7662752.html 
 
Lakonishok, J., & Levi, M. (1982). Weekend effects on stock returns: a note. Journal 
of Finance, 37(3). 883-889. 
 
Lo, A. W. (2004). The Adaptive Markets Hypothesis. The Journal of Portfolio 
Management, 30(5), 15-29. 
 
Markowitz, H. (1952). Portfolio selection. The Journal of Finance, 7(1), 77-91. 
 
McAleer, M. (2014). Asymmetry and leverage in conditional volatility models. 
Econometrics, 2(3), 145-150. 
 
McAleer, M., & Hafner, C. M. (2014). A one line derivation of EGARCH. 
Econometrics, 2(2), 92-97. 
 
Nelson, D. (1991). Conditional heteroskedasticity in asset returns: a new approach. 
Econometrica, 59(2), 347-370. 
 
Pande, V. (2014). The changing healthcare landscape in the United States as a result 
of the passage of the Patient Protection and Affordable Care Act of 2010 and 
the Health Care and Education Reconciliation Act of 2010. International 
Journal of Pharmaceutical and Healthcare Marketing, 8(3). 
 
Poshakwale, S. (1996). Evidence on weak form efficiency and day of the week effect 
in the Indian stock market. Finance India, 10(3), 605-616. 
 
Rodriguez, W. K. (2012). Day of the week effect in Latin American stock markets. 
Revista de Analisis Economico, 27(1), 71-89. 
 
Sharpe, W. F. (1964). Capital asset prices: A theory of market equilibrium under 
conditions of risk. The Journal of Finance, 19(3), 425-442. 
 
Solnik, B., & Bousquet, L. (1990). Day-of-the-week effect on the Paris Bourse. 
Journal of Banking & Finance, 14(2), 461-468. 
 
Day of the week effect in US Biotechnology Stocks 
15 
 
Vernon, J. A., Golec, J. H., & DiMasi, J. A. (2010). Drug development costs when 
financial risk is measured using the Fama–French three‐factor model. Health 
Economics, 19(8), 1002-1005. 
 
Wang, P., & Wang, P. (2011). Asymmetry in return reversals or asymmetry in volatilities?—
New evidence from new markets. Quantitative Finance, 11(2), 271-285. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Day of the week effect in US Biotechnology Stocks 
16 
 
Table 1: Descriptive Statistics and t-tests 
  Period 2002-2015  Jan 01, 2002- March 30, 2010 April 01, 2010- Dec 31, 2015 
Day of the week NBI S&P 500 Difference NBI S&P 500 Difference NBI S&P 500 Difference 
Monday                   
Mean(%) -0.160% -0.030% -0.130% -0.200% -0.010% -0.190% -0.070% -0.020% -0.050% 
St. Dev 0.060% 0.050% 0.050% 0.080% 0.080% 0.060% 0.080% 0.060% 0.080% 
T-test -2.679 
 
  -3.016 
 
  -0.5415 
  
Significance *** 
 
  *** 
 
  
   
N 663 663 663 390 390 390 273 273 273 
Tuesday   
 
    
 
  
   
Mean(%) 0.040% 0.060% -0.020% 0.000% 0.040% -0.040% 0.090% 0.080% 0.010% 
St. Dev 0.050% 0.050% 0.050% 0.070% 0.060% 0.060% 0.070% 0.050% 0.060% 
T-test -0.425 
 
  -0.668 
 
  0.2340 
  
Significance   
 
    
 
  
   
N 723 723 723 426 426 426 297 297 297 
Wednesday   
 
    
 
  
   
Mean(%) 0.050% 0.040% 0.010% 0.080% 0.050% 0.030% 0.010% 0.030% -0.020% 
St. Dev 0.050% 0.040% 0.040% 0.080% 0.060% 0.060% 0.070% 0.060% 0.060% 
T-test 0.269 
 
  0.549 
 
  -0.302 
  
Significance   
 
    
 
  
   
N 725 725 725 426 426 426 299 299 299 
Thursday   
 
    
 
  
   
Mean(%) 0.010% 0.030% -0.020% 0.020% 0.010% 0.010% 0.010% 0.080% -0.070% 
St. Dev 0.060% 0.050% 0.040% 0.080% 0.060% 0.060% 0.080% 0.060% 0.060% 
T-test -0.514 
 
  0.207 
 
  -1.1820 
  
Significance   
 
    
 
  
   
N 709 709 709 418 418 418 291 291 291 
Friday   
 
    
 
  
   
Mean(%) -0.010% 0.030% -0.010% -0.070% 0.000% -0.070% 0.080% 0.010% 0.070% 
St. Dev 0.050% 0.030% 0.040% 0.070% 0.050% 0.060% 0.070% 0.050% 0.060% 
T-test -0.3686 
 
  -1.235 
 
  0.9790 
  
Significance   
 
    
 
  
   
N 705 705 705 415 415 415 290     
*** p<.001, **p<0.01, *p<0.05 
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Table 2: GARCH estimates for for day-of-the-week effect 2002-2015 
  GARCH EGARCH GJR 
NBIreturn Coef. Std. Err. Sig Coef. Std. Err. Sig Coef. Std. Err. Sig 
Tue 0.0006 0.0004   0.0006 0.0004   0.0005 0.0004   
Wed 0.0009 0.0004 *  0.0011 0.0004 * 0.0008 0.0003 * 
Thu 0.0010 0.0004 * 0.0009 0.0004 * 0.0009 0.0003 * 
Fri 0.0009 0.0004 * 0.0009 0.0004  * 0.0009 0.0004 * 
Rf -2.2332 1.7477   -3.6231 2.5226   -3.232 2.6771 
 
Rm-Rf 0.7085 0.0117 *** 0.7252 0.0123 *** 0.7071 0.0116 *** 
SMB 0.4594 0.0261 *** 0.4477 0.0253 *** 0.4608 0.0261 *** 
HML -0.6225 0.0257 *** -0.6344 0.0266 *** -0.6242 0.0255 *** 
UMD 0.0738 0.0169 *** 0.0748 0.0163 ***  0.0726 0.0169 *** 
RNBI-1  0.0481 01279 **  0.0482 0.0113 *** 0.0479 0.0112 *** 
Variance Equation   
 
    
 
  
   
a 0.0841 0.0081 *** 0.0676 0.0131 *** 0.0886 0.0102 *** 
b 0.9082 0.0083 *** 0.9051 0.0091 *** 0.8981 0.0082 *** 
   
 
   -0.0095 0.0080   0.0076 0.0118 
 
Intercept 0.0001 0.0000 *** -0.0306 0.0082 *** 0.0000 0.0000 *** 
*** p<.001, **p<0.01, *p<0.05 
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Table 3: GARCH estimates for for day-of-the-week effect Pre-ACA 
  GARCH EGARCH GJR 
NBIreturn Coef. Std. Err. Sig Coef. Std. Err. Sig Coef. Std. Err. Sig 
Tue 0.0006 0.0006   0.0005 0.0005  0.0005 0.0004   
Wed 0.0013 0.0005 * 0.0012 0.0005 * 0.0008 0.0003 * 
Thu 0.0012 0.0005 * 0.0012 0.0005 * 0.0008 0.0003 * 
Fri 0.0011 0.0004  * 0.0010 0.0004 * 0.0007 0.0003 * 
Rf -2.6367 2.3226   -3.4877 2.8982  -2.9781 1.754 
 
Rm-Rf 0.7675 0.0163 *** 0.7758 0.0163 *** 0.7241 0.0125 *** 
SMB 0.5304 0.0313 *** 0.5214 0.0324 *** 0.4515 0.0257 *** 
HML -0.5605 0.0342 *** -0.5623 0.0341 *** -0.6219 0.0214 *** 
UMD 0.0339 0.0209   0.0367 0.0200  0.0631 0.0712 
 
RNBI-1  0.0731 0.0241 ** 0.0656 0.0136 *** 0.0484 0.0117 *** 
Variance Equation   
 
     
   
a 0.0700 0.009 *** 0.0312 0.0093 *** 0.0679 0.0009 *** 
b 0.9251 0.009 *** 0.9327 0.0026 *** 0.9009 0.0082 *** 
   
 
  -0.0088 0.0112  0.0076 0.0126 
 
Intercept 0.0001 0.0000 *** -0.0616 0.0033 *** 0.0000 0.0000 *** 
*** p<.001, **p<0.01, *p<0.05 
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Table 4: GARCH estimates for for day-of-the-week effect Post-ACA 
  GARCH EGARCH GJR 
NBIreturn Coef. Std. Err. Sig Coef. Std. Err. Sig Coef. Std. Err. Sig 
Tue 0.0009 0.0007   0.0010 0.0008  0.0010 0.0007   
Wed 0.0005 0.0007 
 
0.0012 0.0008  0.0007 0.0006 
 
Thu 0.0010 0.0007 
 
0.0012 0.0005  0.0011 0.0008 
 
Fri 0.0008 0.0007 
 
0.0010 0.0007  0.0007 0.0005 
 
Rf -6.580 9.9071 
 
-5.6771 5.0241  -8.1116 5.625 
 
Rm-Rf 0.5731 0.0192 *** 0.5473 0.0172 *** 0.5694 0.0174 *** 
SMB 0.4141 0.0453 *** 0.4395 0.0408 *** 0.4035 0.0445 *** 
HML -0.7035 0.0474 *** -0.6583 0.0341 *** -0.6844 0.0453 *** 
UMD 0.2841 0.0332 *** 0.3001 0.0317 *** 0.2984 0.0332 *** 
RNBI-1 0.0162 0.0200 
 
0.0258 0.0193  0.0197 0.0242 
 
Variance Equation   
 
   
   
a 0.0912 0.0162 *** 0.0512 0.0093 *** 0.0729 0.0212 *** 
b 0.8904 0.0132 *** 0.9368 0.0008 *** 0.8842 0.0159 *** 
    -0.0106 0.0037 ** 0.0248 0.0256 
 
Intercept 0.0000 0.0000 ** -0.0518 0.0082 *** 0.0000 0.0000 *** 
*** p<.001, **p<0.01, *p<0.05 
 
